John Libbey Eurotext

Epileptic Disorders

MENU

Selective deep brain stimulation in the substantia nigra reduces myoclonus in progressive myoclonic epilepsy: a novel observation and short review of the literature Volume 21, numéro 3, June 2019

  • [Aykutlu et al., 2005] Aykutlu E., Baykan B., Gürses C. Add-on therapy with topiramate in progressive myoclonic epilepsy. Epilepsy Behav. 2005;6:260-263.
  • [Benabid et al., 2002] Benabid A.L., Minotti L., Koudsié A. Antiepileptic effect of high-frequency stimulation of the subthalamic nucleus (corpus luysi) in a case of medically intractable epilepsy caused by focal dysplasia: a 30-month follow-up: technical case report. Neurosurgery. 2002;50:1385-1391. discussion: 1391-2
  • [Berg et al., 1989] Berg K., Wood-Dauphine S., Williams D.G. Measuring balance in the elderly. Preliminary development of an instrument. Physiotherapy Canada. 1989;41:304-311.
  • [Chabardès et al., 2002] Chabardès S., Kahane P., Minotti L. Deep brain stimulation in epilepsy with particular reference to the subthalamic nucleus. Epileptic Disord. 2002;4:S83-93.
  • [Conry, 2004] Conry J.A. Pharmacologic treatment of the catastrophic epilepsies. Epilepsia. 2004;45:12-16.
  • [Crest et al., 2004] Crest C., Dupont S., Leguern E. Levetiracetam in progressive myoclonic epilepsy: an exploratory study in 9 patients. Neurology. 2004;62:640-643.
  • [Genton and Guerrini, 1990] Genton P., Guerrini R. Antimyoclonic effects of alcohol in progressive myoclonus epilepsy. Neurology. 1990;40:1412-1416.
  • [Genton et al., 2016] Genton P., Striano P., Minassian B.A. The history of progressive myoclonus epilepsies. Epileptic Disord. 2016;18:3-10. S2
  • [Krauss and Volkmann, 2004] Krauss J.K., Volkmann J. Tiefe Hirnstimulation. Springer Verlag; 2004.
  • [Mancuso et al., 2006] Mancuso M., Galli R., Pizzanelli C. Antimyoclonic effect of levetiracetam in MERRF syndrome. J Neurol Sci. 2006;243:97-99.
  • [Minassian et al., 2016] Minassian B.A., Striano P., Avanzini G. Progressive myoclonus epilepsy: the gene-empowered era. Epileptic Disord. 2016;18:1-2. S2
  • [Morel, 2007] Morel A. Stereotactic atlas of the human thalamus and the basal ganglia. Informa Healthcare USA; 2007.
  • [Podsiadlo and Richardson, 1991] Podsiadlo D., Richardson S. The timed up & go: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39:142-148.
  • [Pranzatelli and Tate, 2001] Pranzatelli M.R., Tate E.D. Chloral hydrate for progressive myoclonus epilepsy: a new look at an old drug. Pediatr Neurol. 2001;25:385-389.
  • [Shahwan et al., 2005] Shahwan A., Farrell M., Delanty N. Progressive myoclonic epilepsies: a review of genetic and therapeutic aspects. Lancet Neurol. 2005;4:239-248.
  • [Uthman and Reichl, 2002] Uthman B.M., Reichl A. Progressive myoclonic epilepsies. Curr Treat Options Neurol. 2002;4:3-17.
  • [Vesper et al., 2007] Vesper J., Steinhoff B., Rona S. Chronic high-frequency deep brain stimulation of the STN/SNr for progressive myoclonic epilepsy. Epilepsia. 2007;48:1984-1989.
  • [Vossler et al., 2008] Vossler D.G., Conry J.A., Murphy J.V. Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: an open-label study. Epileptic Disord. 2008;10:31-34.
  • [Wille et al., 2011] Wille C., Steinhoff B.J., Altenmüller D.-M. Chronic high-frequency deep-brain stimulation in progressive myoclonic epilepsy in adulthood-report of five cases. Epilepsia. 2011;52:489-496.